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involving assessing temperature sensitivity, the numbers were 11, 12, and 5 for controls (new), 1-time processed, and 10-time processed use, respectively. In vivo testing was performed in sheep undergoing cardiac valve replacement using two new cannulas and three used cannulas (with five total sterilization cycles).
Study design
This was a prospective non-randomised study with concurrent controls, carried out in a single centre. The duration of the follow-up was until the end of testing. No loss to follow-up was reported. An independent laboratory performed biocompatibility testing. Simulation of reuse was conducted employing end-to-end bending, coupling and uncoupling of the connectors, and two 1-hour soaks in plasma at 4 degrees and 40 degrees C, respectively.
Analysis of effectiveness
The principle (intention to treat or treatment completers only) used in the analysis of effectiveness was not explicitly specified. The clinical outcome measures were validity of sterilization (involving eradication Bacillus subtilis spores from the cannulas on each of five consecutive cycles), physical changes (tensile stiffness, yield strength, ultimate tensile strength, elongation-at-break, and energy-to-break), functional integrity, biocompatibility, and in vivo performance in sheep.
Effectiveness results
Sterilization was validated by showing no sign of the test organism post-sterilization. The mechanical properties showed less than 20% change in terms of all variables assessed with comparison to the new cannulas, such that experienced cardiac surgeons did not detect the changes in selective evaluation. In terms of functional testing at room temperature, the reused RMI dual-stage cannulas showed 15% change in body bending stiffness (p<0.001), 21% in tip bending stiffness (NS), and 13% in body tensile stiffness (p=0.004), compared to the use of new cannulas. The corresponding values for RMI single-stage cannulas were 9% (NS), 10% (NS), and 8% (NS), respectively. The reused 3M/Sarns showed no significant changes of wire-reinforced body hardness, nonreinforced body hardness, tip bending stiffness, body tensile stiffness, tip tensile stiffness, tensile yield strength, ultimate tensile strength, tensile elongation-at-break, tensile energy-to-break, shear (tip only) torsional stiffness, torsional yield strength, ultimate torsional strength, torsional angle-at-yield, and torsional energy-to-yield, while body bending stiffness changed by 5%, (p=0.03). New and reused cannulas were not significantly different in terms of clinical properties, even after nine simulated reuses. In vivo testing showed one infected in each of the intervention and control cases. Reused cannulas were successful in the other biocompatibility tests.
Clinical conclusions
The fact that the cannulas passed the other biocompatibility tests, including the muscle implantation test, and that no adverse reactions were observed in the animal model (one of the cannula models evaluated), showed that the reprocessed cannulas are safe.
Measure of benefits used in the economic analysis
No summary benefit measure was identified in the economic analysis because of equal efficacy of the two alternatives, and only separate clinical outcomes were reported.
Direct costs
Costs were not discounted due to the short time frame chosen for the study. Quantities of resource use were not fully reported separately from the costs. Cost items were reported separately. Cost analysis covered the costs of sterilization cycle (including sterilant, consumable supplies, and capital equipment) and reprocessing costs including labour costs. Cost calculation for the reuse option was based on four-time cannula reuse. The source of cost data for reprocessing costs including labour costs was the Cleveland Clinic Foundation. The date of the price data was not explicitly specified.
